YS Biopharma Co. Ltd. (YS)
YS Biopharma Statistics
Share Statistics
YS Biopharma has 188.33M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 188.33M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 17.1M |
| Failed to Deliver (FTD) Shares | 540 |
| FTD / Avg. Volume | 0.41% |
Short Selling Information
The latest short interest is 38.89K, so 0.02% of the outstanding shares have been sold short.
| Short Interest | 38.89K |
| Short % of Shares Out | 0.02% |
| Short % of Float | 0.03% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -7.03 and the forward PE ratio is null. YS Biopharma's PEG ratio is -0.2.
| PE Ratio | -7.03 |
| Forward PE | n/a |
| PS Ratio | 1.49 |
| Forward PS | null |
| PB Ratio | 1.4 |
| P/FCF Ratio | -4.27 |
| PEG Ratio | -0.2 |
Enterprise Valuation
YS Biopharma has an Enterprise Value (EV) of 1.15B.
| EV / Sales | 1.67 |
| EV / EBITDA | -14.98 |
| EV / EBIT | -6.31 |
| EV / FCF | -4.81 |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.68.
| Current Ratio | 1.57 |
| Quick Ratio | 1.29 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | -6.49 |
| Debt / FCF | -2.08 |
| Interest Coverage | -4.52 |
Financial Efficiency
Return on Equity is -19.97% and Return on Invested Capital is -11.45%.
| Return on Equity | -19.97% |
| Return on Assets | -8.46% |
| Return on Invested Capital | -11.45% |
| Revenue Per Employee | $889.01K |
| Profits Per Employee | $-188.2K |
| Employee Count | 773 |
| Asset Turnover | 0.4 |
| Inventory Turnover | 0.83 |
Taxes
| Income Tax | 1.13M |
| Effective Tax Rate | -0.79% |
Stock Price Statistics
The stock price has increased by 37.65% in the last 52 weeks. The beta is 0.54, so YS Biopharma's price volatility has been higher than the market average.
| Beta | 0.54 |
| 52-Week Price Change | 37.65% |
| 50-Day Moving Average | 0.84 |
| 200-Day Moving Average | 0.67 |
| Relative Strength Index (RSI) | 41.08 |
| Average Volume (20 Days) | 130.56K |
Income Statement
In the last 12 months, YS Biopharma had revenue of 687.2M and earned -145.48M in profits. Earnings per share was -1.56.
| Revenue | 687.2M |
| Gross Profit | 533.84M |
| Operating Income | -139.38M |
| Net Income | -145.48M |
| EBITDA | -76.82M |
| EBIT | -108.7M |
| Earnings Per Share (EPS) | -1.56 |
Balance Sheet
The company has 370.11M in cash and 498.63M in debt, giving a net cash position of -128.52M.
| Cash & Cash Equivalents | 370.11M |
| Total Debt | 498.63M |
| Net Cash | -128.52M |
| Retained Earnings | -1.87B |
| Total Assets | 1.51B |
| Working Capital | -56.24M |
Cash Flow
In the last 12 months, operating cash flow was -182.47M and capital expenditures -57.05M, giving a free cash flow of -239.52M.
| Operating Cash Flow | -182.47M |
| Capital Expenditures | -57.05M |
| Free Cash Flow | -239.52M |
| FCF Per Share | -2.57 |
Margins
Gross margin is 77.68%, with operating and profit margins of -20.28% and -21.17%.
| Gross Margin | 77.68% |
| Operating Margin | -20.28% |
| Pretax Margin | -21% |
| Profit Margin | -21.17% |
| EBITDA Margin | -11.18% |
| EBIT Margin | -20.28% |
| FCF Margin | -34.85% |
Dividends & Yields
YS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -14.23% |
| FCF Yield | -23.43% |
Analyst Forecast
Currently there are no analyst rating for YS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -2.16 |
| Piotroski F-Score | 4 |